Next generation

full-body embolic
protection for TAVI

The European Commission Horizon 2020
Program Backs Filterlex’s
Embolic Protection Device - CAPTIS

€2.1M Grant to support Filterlex’s CAPTIS clinical trials

READ MORE

FILTERLEX

Our goal is to develop the next generation embolic protection device to reduce the risk of stroke and other complications during catheter-based structural heart procedures. The CAPTIS® concept and unique structure was created out of deep understanding and knowledge of the TAVI procedure and the unmet need.

THE NEED

During catheter-based, left-heart procedures such as TAVI, embolic particles are often released to the blood flow. Particles migration to the brain may cause a spectrum of neurological deficiencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia.

CAPTIS®

The CAPTIS® is a next-generation full-body embolic protection device, easily and intuitively deployed and retrieved. The device is securely positioned in the aorta, protects its surface while facilitating a seamless TAVI procedure. Its distinctive, triple action design provides a full-body embolic protection by deflecting, capturing and removing embolic particles. Uniquely, it requires no additional access and does not interfere to the procedure workflow.

CAPTIS® UNIQUE BENEFITS

Full-body embolic protection

Embolic capture and extraction

Easy and intuitive deployment and retrieval

Aortic surface protection

Fully integrates with the procedure

No interference to procedure devices

Stable and safe anchoring

Very stable aortic arch deflector

Accommodates anatomical variations

NEWS

The European Commission Horizon 2020 Program Backs Filterlex’s Embolic Protection Device - CAPTIS

Sep 16 // 2019

€2.1M Grant to support Filterlex’s CAPTIS clinical trials

Read more >> 

Best Innovation Award at the EuroPCR

May 6 // 2019

Filterlex receives the Best Innovation Award at the EuroPCR 2019 for the CAPTIS Embolic Protection Device for TAVI.

Read more: https://www.jondehaanfoundation.org/award-2019

THE TEAM

Sigal pic for web

Sigal Eli

Inventor, Founder & CEO

Eyal Teichman

Founder & CTO

Giora Weisz, MD

Founder & Chairman of Advisory Board

Dr. Shimon Eckhouse​

Chairman​

Dr. Judith Zilberstein

Director

Ron Davidson

Founder & Active Board Member

This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 881076

filterlex 2019 © All rights reserved
face 2 face – web development

Sigal Eli

Inventor, Founder & CEO

Sigal is an Interventional cardiology imaging expert with extensive experience in TAVR and other catheter-based procedures including EP, LAAC and PCI. She served as a clinical and training specialist at Paieon Medical and supported over 300 TAVR procedures in 20 medical centers worldwide. Sigal also brings extensive experience as a Marketing Communications Manager. Sigal is the inventor of Filterlex’ patent.

Eyal Teichman

Founder & CTO

Eyal is a seasoned entrepreneur and CTO of several medical device start-ups. He is a mechanical engineer with over 30 years of R&D experience, 15 of them in implantable devices in the cardiovascular field. Eyal serves as the CTO of Sil Vascular and Cologuard and previously held senior R&D positions at Labcoat, Cappella, Talia Technology, Celtronix and Orbotech. Eyal holds a BSc in Mechanical Engineering from Ben Gurion University.

Giora Weisz, MD

Founder & Chairman of Advisory Board

Interventional Cardiologist at Columbia University in New York, NY. Previously, Director of Interventional Cardiology at Montefiore Medical Center, and faculty of the Cardiovascular Research Foundation in New York, NY. An internationally recognized researcher focused on innovative technologies in cardiovascular medicine. Pioneered the use of novel robotic-enhanced interventions, including navigation and positioning technologies. Has been the Principal Investigator for pivotal clinical studies leading to FDA approval of cutting-edge technologies.

Dr. Shimon Eckhouse

Chairman

Dr. Eckhouse, one of Israel’s leading medical entrepreneurs, is the owner of Alon MedTech Ventures incubator. He takes an active role in choosing projects and accompanying portfolio companies to success by being involved in the technological and business aspects of the portfolio companies. Dr. Eckhouse has founded and invested in numerous medical technology firms, two of which are leading international companies, (ESC Medical [Lumenis] and Syneron Medical), both traded on NASDAQ.

Dr. Judith Zilberstein

Director

Dr. Zilberstein has more than 20 years’ experience in the medical device industry; Vast experience in investments in the Healthcare and nanotech fields. As CEO and CTO at Alon MedTech Ventures, her activities include choosing projects, advancing them into companies and guiding their scientific activity. Further, she assists in structuring marketing strategy and forges scientific and commercial ties with external groups.

Ron Davidson

Founder and Active Board Member

Ron has 20 years of experience in managing and accelerating companies in the healthcare field. He led two companies from early stage to successful acquisitions by multinational companies. Ron previously served as the CEO of Flight Medical, Paieon Medical, Medtechnica Hi-Tech and NexSig and was the senior VP of sales and operations of Medcon, acquired by McKesson. Ron holds a BSc in Mathematics and Computer Sciences and an MBA from Tel-Aviv University.